Compare · ENZ vs UNH
ENZ vs UNH
Side-by-side comparison of Enzo Biochem Inc. (ENZ) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ENZ and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH is the larger of the two at $382.83B, about 2475.9x ENZ ($154.6M).
- UNH has hit the wire 13 times in the past 4 weeks while ENZ has been quiet.
- UNH has more recent analyst coverage (25 ratings vs 0 for ENZ).
- Company
- Enzo Biochem Inc.
- UnitedHealth Group Incorporated
- Price
- $0.32-15.01%
- $428.48+1.57%
- Market cap
- $154.6M
- $382.83B
- 1M return
- -
- +6.37%
- 1Y return
- -
- +51.25%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 1988
- News (4w)
- 0
- 13
- Recent ratings
- 0
- 25
Enzo Biochem Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New York and New Jersey; and a free-standing ÂSTAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest ENZ
- Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
- Enzo Biochem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
- Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 25 filed by Enzo Biochem Inc.
- Enzo Biochem Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
- Enzo Biochem Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
- SEC Form 10-Q filed by Enzo Biochem Inc.
Latest UNH
- UnitedHealth upgraded by Robert W. Baird with a new price target
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports Second Quarter 2026 Results
- UnitedHealthcare Launches New Spending Account Benefit, Putting More Choice in the Hands of Consumers
- Director Noseworthy John H was granted 206 shares, increasing direct ownership by 3% to 7,616 units (SEC Form 4)
- Director Montgomery Rice Valerie Md was granted 220 shares, increasing direct ownership by 3% to 7,876 units (SEC Form 4)
- Director Mcnabb Frederick William Iii was granted 250 shares, increasing direct ownership by 2% to 15,462 units (SEC Form 4)
- Director Gottlieb Scott was granted 210 shares, increasing direct ownership by 47% to 659 units (SEC Form 4)
- Director Gil Kristen was granted 206 shares, increasing direct ownership by 9% to 2,617 units (SEC Form 4)
- Director Garcia Paul R was granted 220 shares, increasing direct ownership by 6% to 3,906 units (SEC Form 4)